Article

Anti-Aβ immunotherapy-mediated amyloid clearance attenuates microglial activation without inducing exhaustion at residual plaques

2025-04-17

Abstract excerpt

Anti-amyloid β-peptide (Aβ) immunotherapy was developed to reduce amyloid plaque pathology and slow cognitive decline during progression of Alzheimer’s disease. Efficient amyloid plaque clearance has been proven in clinical trials testing anti-Aβ antibodies, with the impact on cognitive endpoints correlating with the extent of plaque removal. However, treatment is associated with adverse side-effects, such as oede...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 73597d0b-4aa2-5a97-9593-331868d51395
DOI: 10.1101/2025.04.10.645950

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-Aβ immunotherapy-mediated amyloid clearance attenuates microglial activation without inducing exhaustion at residual plaquesDOI 10.1101/2025.04.10.645950Read

Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer's Disease.Semantic proximity Read

Activated microglia mitigate Aβ-associated tau seeding and spreading.Semantic proximity Read

Microglia initially seed and later reshape amyloid plaques in Alzheimer’s diseaseSemantic proximity Read

Phagocytes as Plaque Catalysts: Human Macrophages Actively Generate Pathogenic Aβ42 Fibrils with Seeding and Cross-Seeding PotencySemantic proximity Read

The TREM2 targeting small molecule Sob-AM2 improves cognition independent of Aβ plaque alteration in 5xFAD miceSemantic proximity Read

Beneficial Effect of ACI-24 Vaccination on Aβ Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model.Semantic proximity Read

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.Semantic proximity Read

Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer's disease.Semantic proximity Read

Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse modelsSemantic proximity Read

Longitudinal increase of CSF soluble TREM2 is driven by early aggregation of Aβ42 and associates with slower amyloid deposition and clinical decline in autosomal-dominant Alzheimer’s diseaseSemantic proximity Read

BAC Transgenic Expression of Human TREM2-R47H Remodels Amyloid Plaques but Unable to Reprogram Plaque-associated Microglial Reactivity in 5xFAD MiceSemantic proximity Read

Intravenous anti-Aβ immunotherapy acutely increases cerebral amyloid angiopathy and vascular damages in APOE4 miceSemantic proximity Read